Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Oxbryta™ (voxelotor) – New orphan drug approval
November 25, 2019 - The FDA announced the approval of Global Blood Therapeutics’ Oxbryta (voxelotor), for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.
